The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Akero To Contact Him Directly To Discuss Their Options If you ...
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
May 10, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by ...
Investors suffering losses on their Akero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 215-638-4847 or by email to ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage ...
Hosted on MSN25d
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024Akero Therapeutics (NASDAQ:AKRO) just reported results for the first quarter of 2024. Akero Therapeutics reported earnings per share of -90 cents. This was above the analyst estimate for EPS of ...
May 10, 2024 (GLOBE NEWSWIRE) -- Akero Ther SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback